HLB Life Science R&D Selected for Ministry of Health AI Oncology Drug Development Project
HLB Life Science R&D has been selected for a government project on artificial intelligence (AI)-driven drug development, overseen by the Ministry of Health and Welfare.
According to HLB Life Science on May 26, the project has a total research budget of 2.2 billion won and will be carried out over three years until 2028. Arontier will participate as the lead organization, while the Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub) and HLB Life Science R&D will serve as joint research institutions. The goal is to use AI to identify oncology drug candidates from the initial discovery stage to the lead compound stage, with HLB Life Science R&D responsible for the non-clinical trials in this project.
HLB Life Science will validate the development potential of AI-based drug candidates through non-clinical research, including efficacy evaluations and animal testing of candidate substances. Additionally, the company plans to accumulate foundational data on the efficacy and safety of the candidates identified through this project, thereby increasing the potential for further development.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An HLB Life Science R&D representative stated, "This project aims to enhance the development potential of oncology drug candidates by combining AI-based drug discovery technologies with non-clinical validation capabilities," adding, "We will do our utmost to achieve meaningful outcomes in collaboration with our joint research institutions, leveraging our expertise in non-clinical studies."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.